Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07118085) titled 'A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Condition:
Healthy Postmenopausal Women
Intervention:
Drug: experimental Arm IMC-003
Recruitment Status: Not...